EP1001985A1 - Domaines kringle 1-5 de plasminogene permettant de moduler l'angiogenese in vivo - Google Patents

Domaines kringle 1-5 de plasminogene permettant de moduler l'angiogenese in vivo

Info

Publication number
EP1001985A1
EP1001985A1 EP98930036A EP98930036A EP1001985A1 EP 1001985 A1 EP1001985 A1 EP 1001985A1 EP 98930036 A EP98930036 A EP 98930036A EP 98930036 A EP98930036 A EP 98930036A EP 1001985 A1 EP1001985 A1 EP 1001985A1
Authority
EP
European Patent Office
Prior art keywords
inhibitor
cells
analogue
protein
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98930036A
Other languages
German (de)
English (en)
Inventor
Cao Yihai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karolinska Innovations AB
Original Assignee
Karolinska Innovations AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9703057A external-priority patent/SE9703057D0/xx
Application filed by Karolinska Innovations AB filed Critical Karolinska Innovations AB
Publication of EP1001985A1 publication Critical patent/EP1001985A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to novel endothelial cell proliferation inhibitors.
  • the inhibitors are extraordinarly potent in inhibiting angiogenesis related diseases and modulating angiogenic processes.
  • the present invention relates to methods of treating a human or animal having an angiogenic disease by adnjinistrering an inhibitor according to the invention thereto.
  • angiogenesis means the generation of new blood vessels into a tissue or organ, and involves endothelial cell proliferation. Under normal physiological conditions, humans or animals undergo angiogenesis only in very specific restricted situations. For example, angiogenesis is normally observed in wound healing, fetal and embryonal develop- ment and formation of the corpus luteum, endometrium and placenta.
  • endothelium means a thin layer of flat epithelial cells that lines serous cavities, lymph vessels and blood vessels.
  • Endothelial cells and pericytes surrounded by a basement membrane, form capillary blood vessels.
  • Angiogenesis begins with the erosion of the basement membrane by enzymes released by endothelial cells and leukocytes.
  • the endothelial cells which line the lumen of blood vessels, then protrude through the basement membrane.
  • Angiogenic stimulants induce the endothelial cells to migrate through the eroded basement membrane.
  • the migrating cells form a "sprout" off the parent blood vessel, whe- re the endothelial cells undergo mitosis and proliferate.
  • the endothelial sprouts merge with each other to form capillary loops, creating the new blood vessel.
  • Persistent, unregulated angiogenesis occurs in a multiplicity of disease states, tumor metastasis and abnormal growth by endothelial cells and supports the pathological damage seen in these conditions.
  • the diverse pathological disease states in which unregulated angiogenesis is present have been grouped together as angiogenic dependent or angiogenesis associated diseases.
  • Tumor angiogenesis Therapeutic implications. N. Engl. Jour. Med. 285: 1182-1186, 1971.
  • Tumor "take” is currently understood to indicate a prevascular phase of tumor growth in which a population of tumor cells occupying a few cubic millimeters volume, and not exceeding a few million cells, can survive on existing host microvessels. Expansion of tumor volume beyond this phase requires the induction of new capillary blood vessels. For example, pulmonary micrometastases in the early prevascular phase in mice would be un- detectable except by high power microscopy on histological sections.
  • Examples of the indirect evidence which support this concept include: (1) The growth rate of tumors implanted in subcutaneous transparent chambers in mice is slow and linear before neovascularization, and rapid and nearly exponential after neovascularization. (Algire GH, et al. Vascular reac- tionis of normal and malignant tumors in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants.; J Natl. Cancer Inst.6:73-85, 1945). (2) Tumors grown in isolated perfused organs where blood vessels do not proliferate are limited to 1-2 mm 3 but expand rapidly to > 1000 times this volume when they are transplanted to mice and become neovascularized. (Folkman J, et al., Tumor behavior in isolated perfused organs: In vitro growth and metastasis of biopsy material in rabbit thyroid and canine intestinal segments. Annals of Surgery 164:491-502, 1966).
  • Tumor growth in the avascular cornea proceeds slowly and at a linear rate, but switches to exponential growth after neovascularization.
  • Tumor growth and neov ascularization An ex- perimental model using the rabbit cornea. J. Natl. Cancer Institute 52:41- 427, 1974).
  • Tumors suspended in the aqueous fluid of the anterior chamber of the rabbit eye remain viable, avascular and limited in size to ⁇ 1 mm ⁇ . Once they are implanted on the iris vascular bed, they become neovascularized and grow rapidly, reaching 16,000 times their original volume within 2 weeks. (Gimbrone MA Jr., et al., Tumor dormancy in vivo by prevention of neovascularization, J. Exp. Med. 136:261-276).
  • Tumors are generally avascular up to 1 mm in diameter, but are neovascularized beyond that diameter.
  • pre-vascular hyperplastic islets are limited in size to ⁇ 1 mm 3 .
  • 4- 10% of the islets become neovascularized, and from these islets arise large vascularized tumors of more than 1000 times the volume of the pre-vascular islets.
  • VEGF vascular endothelial growth factor
  • Anti-bFGF monoclonal antibody causes 70% inhibition of growth of a mouse tumor which is dependent upon secretion of bFGF as its only mediator of angiogenesis. The antibody does not inhibit growth of the tumor cells in vitro. (Hori A, et al., Suppression of solid tumor growth by immunoneut- ralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Research, 51:6180-6184, 1991).
  • bFGF Intraperitoneal injection of bFGF enhances growth of a primary tumor and its metastases by stimulating growth of capillary endothelial cells in the tumor.
  • the tumor cells themselves lack receptors for bFGF, and bFGF is not a mitogen for the tumor cells in vitro.
  • a specific angiogenesis inhibitor (AGM-1470) inhibits tumor growth and metastases in vivo, but is much less active in inhibiting tumor cell proliferation in vitro. It inhibits vascular endothelial cell proliferation half- maximally at 4 logs lower concentration than it inhibits tumor cell proliferation.
  • AGM-1470 A specific angiogenesis inhibitor
  • angiogenesis plays a major role in the metastasis of a cancer. If this angiogenic activity could be repressed or eliminated, or otherwise controlled and modulated, then the tumor, although present, would not grow. In the disease state, prevention of angiogenesis could avert the damage caused by the invasion of the new microvascular system. Therapies directed at control of the angiogenic processes could lead to the abrogation or mitigation of these diseases.
  • compositions and methods by which endothelial cell proliferation, such as the unwanted growth of blood vessels, especially into tumors, may be inhibited there is also a need for methods for detecting, measuring and localizing such compositions.
  • Such compositions should be able to overcome the activity of en- dogenous growth factors in premetastatic tumors and prevent the formation of the capillaries in the tumors, thereby inhibiting growth of the tumors.
  • the compositions, fragments of such compositions and antibodies specific to said compositions should be able to modulate the formation of capillaries in other angiogenic processes, such as wound healing and repro- duction.
  • compositions and methods for inhibiting angiogenesis should preferably be non-toxic and produce few side effects. Also needed is a method for detecting, measuring and localizing the binding sites for the composition as well as sites of biosynthesis of the composition.
  • the compositions and fragments of the compositions should be capable of being con- jugated to other molecules for both radioactive and non-radioactive labeling purposes.
  • angiostatin the first four kringle regions, nos. 1-4, of plas- minogen, also denoted angiostatin, as a composition for the above defined purposes.
  • angiostatin used as a medicament for human patients, angiostatin would have to be administered in kilograms to be effective, which of course would put severe limitations to the use thereof due to practical reasons.
  • Another drawback lies in the amounts which would be necessary to produce due to said low effect, making such a product quite costly.
  • the object of the present invention is to fulfill above defined need. This is accomplished by the present invention, which relates to a protein capable of modulating or regulating, e.g. inhibiting, the endothelial cell proliferation in in vitro and angiogenesis in in vivo assays.
  • the invention also relates to any nucleic acid encoding such a protein.
  • Figure 1 shows a proteolytic human kringle 1-5 (Kl-5) fragment, scemati- cally and purified on a gel.
  • Figure 2 A-B show the anti-endothelial cell proliferation activity of Kl-5, while 2 C-D show the inhibition of capillary endothelial cell proliferation.
  • Figure 3 shows the morphology of K 1-5 treated endothelial cells.
  • Figure 4 shows the synergistic suppression of endothelial cell grpwth by angiostatin and K5.
  • Figure 5 shows the anti-angiogenic effect of K 1-5 according to the invention on the chick embryo chorioallantoic membrane (CAM).
  • Figure 6 shows suppression of primary tumor growth by K 1-5 according to the invention, comparing mice treated with K 1-5 with saline treated mice.
  • Figure 7 shows detection of microvessel density by immunohistochemical staining of tumor tissue sections with anti-vWF antibodies.
  • the present invention relates to a protein as defined by claim 1.
  • the protein according to the invention is comprised of at least about 50% of the amino acid sequence which the human kringle 1-5 sequence as disclosed in SEQ ID NO. 1 and the mouse kringle 1-5 as disclosed in SEQ ID NO. 2 has in common.
  • the protein accordingto the invention comprises about 60-70% of the amino acid sequence which SEQ ID NO 1 an 2 has in common and more specifi- cally essentially all of that sequence.
  • the protein according to the invention is comprised of essential parts the human amino acid sequence and in an alternative embodiment, the protein according to the invention is comprised of essentially all of the mouse amino acid sequence. It is to be understood that in all embodiments of the protein ac- cording to the invention, analogues and functional fragments thereof are also encompassed.
  • the protein according to the invention has a molecular weight of between about 50 to about 65 kilodaltons, as determined by non- reducing polyacrylamide gel electrophoresis.
  • the molecular weight depends inter alia on whether the molecule has been glycosylated or not, which in turn depends on how it has been produced.
  • the molecule according to the invention exhibits an amino acid sequence which is substantially similar to that of a plasminogen fragment comprised of Lys 78-Arg 530 of a plasmi- nogen molecule. In the literature, the identity of the amino acids with which the plasminogen starts and ends have been debated.
  • the most important feature of the molecule according to the invention is that it possesses the advantageous angiogenic properties described herein.
  • the sequence which the present molecule resembles may start with Lys 77 or Lys 78 and, correspondingly, it may end with Arg 529 or
  • a preferred embodiment of the invention is a molecule, which mo- re specifically has a molecular weight of about 50 to about 60 kilodalton, preferably about 53 to about 57 kilodalton and most preferred about 55 kilodalton.
  • the plasminogen fragment according to the broad definition given above i.e. comprised of the amino acid sequence Lys78-Arg 530 of plasmi- nogen, is also denoted Kl-5, as it comprises the first five kringle domains of plasminogen. Even though the fifth domain indeed has been known to exist before, the general opinion of the experts within this field has been that kringle no. 5 has not contributed to, or shared, the angiogenic properties of angiostatin.
  • the present inventor has now been able to disclose extremely promising results for such new fragments, or molecules exibiting sequences substantially similar to such fragments, which compared to the prior angiostatin compositions quite surprisingly are superior in the present context.
  • the molecule according to the invention is also more preferred than the prior angiostatin compounds, since the present molecule is larger. Consequently, the present molecule is more stable and therefore more favourable for use as a medicament and in medicinal compositions.
  • the present invention relates to a molecule as defined above, wherein the plasminogen fragment is similar to a fragment selected from the group consisting of human plasminogen, murine plasminogen, bovine plasminogen, Rhesus plasminogen and porcine plasminogen.
  • the molecule, or protein, according to the present is capable of inhibiting endothelial cell proliferation in in vitro assays.
  • the protein comprises essentially all of the sequence of SEQ ID NO. 1 or any functional fragment or analogue thereof. In an alternative embodiment, the protein comprises essentially all of the sequence of SEQ ID NO. 2 or any functional fragment or analogue thereof. Said function relates to the advantageous endothelial cell proliferation regulating property that according to the invention has been associated with Kl-5 of plasminogen.
  • Another object of the present invention is the use of a molecule according to the invention, such as Kl-5, as a medicament.
  • the invention also relates to the use of a molecule as defined above for the manufacture of a medicament for modulating, e.g. inhibiting, endothelial cell proliferation, for example for treating angiogenesis associated conditions or diseases, such as tumor growth, e.g. cancer, diabetes etc.
  • the invention also relates to a pharmaceutical or veterinary composition, which comprises a molecule according to the invention as well as one or more pharmaceutically acceptable carriers and/or excipients.
  • the composition may be administered in a variety of unit dosage forms depending upon the method of administration, e.g parennteral, topical, oral or local adnrinistration, for prophylactic and/or therapeutic treatment.
  • unit dosage forms suitable for aroal administration include powder, tablets, pills, capsules and lozenges.
  • a variety of carriers may be used, such as aqueous carriers, e.g. buffered saline etc. These solutions are free of undesirable matter.
  • compositions may also include pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, toxicity adjusting agents and the like, e.g. sodium acetate, sodium chloride, potassium chloride, cal- cium chloride etc.
  • auxiliary substances e.g. sodium acetate, sodium chloride, potassium chloride, cal- cium chloride etc.
  • compositions, or preparation, according o the present invention may be administered in a much lower dosage and the use thereof is thus superior to that of known angiostastin compositions. Consequently, the use of a pharmaceutical preparation comprising Kl-5, when compared, to use of angiostatin, is easier to administer due to the smaller amount needed, which smaller dose also results in a cheaper medicament.
  • the composition comprises a molecule or protein, which is capable of inhibiting cancer metastases.
  • the half maximal concentration (EC50) of the molecule according to the present invention for the inhibition of endothelial cell proliferation is about 50 pM, to be compared with the EC50 value for angiostatin, which is 130 nM.
  • EC50 half maximal concentration
  • the molecule according to the invention is also more stable in the human or animal body than the prior art compounds, probobly due to a higher resistence against proteases and other enzymes present. In other words, it exhibits a longer half-time, which is advantageous as it enables a less frequent administration as well as lower amounts.
  • a Kl-5 preparation according to the present invention is more convenient for the patient treated therewith and also less costly than the angiostatin or K5 compounds of the prior art.
  • Another object of the present invention is a nucleic acid, such as a DNA or RNA, encoding any molecule according to the invention.
  • a cDNA sequence which is complementary to such a sequence is also encompassed.
  • further object of the invention is any nucleic acid which under stringent conditions hybridizes specifically to one of the above defined nucleic acids.
  • hybridising specifically to refers to the binding, duplexing or hybridizing of a molecule only to a particular nucleotide sequence under stringent conditions when that sequence is present in a complex mixture of DNA or RNA.
  • stringent conditions refers to conditions, under which a probe will hybridize to its target sequence, but to no other sequences.
  • Stringent conditions are sequence- dependent and will be different in different circumstances. The one skilled in this field will easily choose the suitable conditions in the present context. Generally, stringent conditions re selected to be about 5°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M Na ion, such as about 0.01-1.0 M, at a pH of about 7.0-8.3 and the temperature is between about 30°C and 60°C, depending on the length of the nucleotide. Stringent conditions may also be achieved by the addition of destabilizing agents, such as formamide. Such a nucleotide according to the invention may be of any length in accordance with the above defined.
  • the nucleic acids according to the invention are cloned or amplified by in vitro methods, such as polymerase chain reaction (PCR), the ligase chain reaction (LCR), the transcription-based amplification system (TAS), etc.
  • PCR polymerase chain reaction
  • LCR ligase chain reaction
  • TAS transcription-based amplification system
  • a wide variety of cloning and in vitro amplification methods are wll known to persons of skill, see e.g. Berger and Kimmel, Guide to Molecular Cloning Techniques, Methods in Enzymology 152 Academic Press, Inc., San Diego, CA (Berger); Sambrook et al., (1989) Molecular Cloning - A Laboratory Manual, vol 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor Press, NY; Current pRotocols in Molecular Biology, F.M.
  • the invention relates to a peptide, polypeptide or protein encoded by a nucleic acid according to the invention. General methods of preparation of such molecules is further disclosed below in the section regarding uses.
  • Another aspect of the present invention is an antibody raised against a peptide, polypeptide or protein according to the invention.
  • an immunogen preferably a purified polypeptide, a polypeptide coupled to an appropriate carrier (e.g. GST, keyhole limpet hemanocyanin etc.), or a polypeptide incorporated into an immunization vector such as a recombinant vaccinia virus (see US patent no. 4 722 848) is mixed with an adjuvant and animals are immunized with the mixture.
  • the animal's immune response to the immunogen preparation is monitored by taking test bleeds and determining the titer of the reactivity to the polypeptide of interest.
  • blood is collected from the animal and antisera are prepared. Further fractionation of the an- tisera to enrich for antibodies reactive to the polypeptide is performed where desired (see. e.g. Coligan (1991) Current Protocols in Immunology, Wiley/Greene, NY; and Harlow and Lane (1989) Antibodies: A laboratory manual, Cold Spring Harbor Press, NY).
  • the methods according to the invention can involve transfecting cells of a mammal with a vector expressing a polypeptide or antibody according to the invention.
  • the transfec- tion can be in vivo or ex vivo. Ex vivo transfection is suitably followed by re-mfusing the cells into the organism.
  • Other methods involve administering to the mammal, e.g. a human, of a therapeutically effective dose of a composition comprising a polypeptide according to the invention and a pharma- cological excipient and/or carrier.
  • One further object of the present invention is to provide a method of treating diseases and processes that are mediated by endothelial cell proliferation, especially angiogenesis.
  • One such disease which may be treated is cancer.
  • the invention relates to a method of treating a human or animal with an angiogenic disease comprising administering, to said human or animal, a molecule or protein having a molecular weight of approximately 50 - 65 kilodaltons as determined by non-reducing polyacrylamide gel electrophoresis and having an amino acid sequence substantially similar to that of a plasminogen fragment comprised of Lys 78-Arg 530 of a plasminogen molecule.
  • the protein has a molecular weight of approximately 50 - 60 kilodaltons, preferably 53 -57 kilodalton and most preferred approximately 55 kilodalton.
  • the method according to the invention may use a molecule substantially similar to a plasminogen fragment, which is selected from the group consis- ting of human plasminogen, murine plasminogen, bovine plasminogen, Rhesus plasminogen and porcine plasminogen.
  • the present invention encompasses protein molecules analogues of kringle 1-5 of plasminogen as well as methods of use thereof.
  • the new part which has been added to the previously known angiostatin molecule is accordingly kringle no 5 of plasminogen, which is separately described in detail below.
  • Previous tests have shown that kringle no 5 of plasminogen possesses a certain inhibitory effect alone (see US Patent Application No 08/763 528, filed on December 12, 1996, by the present inventor, which application was secret at the time of the filing of the present application and which is hereby included via reference).
  • the effect of K5 alone is hundreds of times weaker that the effect of the molecule according to the present invention.
  • the endothelial cell proliferation inhibitory effect of the molecule according to the present invention is far superior than a mere addition of the effects of K 1-4 and K-5.
  • the present invention also encompasses diagnostic and therapeutic methods for detecting the presence or absence of the inhibiting peptide in body fluids, and for administration of the peptide or antibodies that specifically bind the peptide to patients in need of therapeucically effective amounts of such compounds to regulate endothelial cell proliferation.
  • the inhibitory peptide may be used in conjunction with in vitro proliferating endothelial cell cultures to test for compounds that mitigate the inhibitory ef- fects of the peptide - i.e. to screen for growth factors or other compounds capable of overcoming or reversing the inhibition of endothelial cell proliferation.
  • another aspectof the invention is a screening asay, wherein a nucleic acid, a_protein, a peptide or a polypeptide according to the invention is used.
  • the present invention also encompasses screening assays aimed at the detection of molecules useful as alternatives to Kl-5, which exhibits the same function but are more desirable e-g- due to a smaller molecular weight.
  • the methods according to the invention are aimed at the detection of peptide or polypeptides, or even proteins, that bind to the same target as Kl-5 and therefore exhibit an equivalent therapeutic effect.
  • the peptides or polypeptides, or even proteins detected by the method of the invention are also within the scope of the invention and thus, a further aspect of the invention is any peptide, polypeptide, or protein that bind to the same receptor as Kl-5 as defined by the invention, preferably by SEQ ID NO. 1 and SEQ ID NO 2.
  • Still another object of the present invention is to provide a diagnostic or prognostic method, or assay, and kit for detecting the presence and/or amount of the inhibitor in biological fluid samples, such as a body fluid or tissue.
  • the invention also relates to to histochemical kits for localization of the inhibitor defined herein.
  • Another object of the invention is to provide molecular probes to monitor inhibitor biosynthesis and degradation, antibodies that are specific for the inhibitor according to the invention, the development of peptide agonists and antagonists to said inhibitor's receptor, anti-inhibitor receptor-specific antibody agonists and antagonists, and to cytotoxic agents linked to the in- hibitor.
  • angiogenesis
  • Still another object of the present invention is to provide a composition comprising the endothelial cell proliferation inhibitor of the present invention or inhibitor peptide fragment linked to a cytotoxic agent.
  • Another object ot the present invention is to provide a method for targeted delivery of inhibitor-related compositions to specific locations.
  • Yet another object of the invention is to provide compositions and methods useful for gene therapy for the modulation of endothelial cell proliferation, such as angiogenic processes.
  • Fig. 1 Proteolytic human Kl-5 fragment.
  • Kringle 1-5 fragment of human plasminogen was obtained by digestion of Glu 1 plasminogen with urokinase-activated plasmin. The cleavage sites of plasmin is located between the double positively charged Lys76 (77) and Lys77 (78) at the N-terrriinus, and Arg529 (530) and Lys530 (531) and the C-terminus.
  • the Kl-5 fragment containing the region between Lys77- Arg529 was purified by lysine-Sepharose chromatography followed by a Sephadex G-75 column.
  • the purified Kl-5 was analyzed on a 10-15% SDS gradient polyacrylamide gel. The molecular standards in kilodaltons are indicated on the left.
  • Fig. 2 Anti-endothelial cell proliferative activity and Inhibition of capillary endothelial cell proliferation.
  • Kl-5 purified from the plasmin digestion of human plasminogen was assayed on bovine cappilary endothelial (BCE) cells in the presence of 1 ng/ml bFGF in a 72-h proliferation assay as described previously (Cao et al., J. Biol. Chem 271,29461-29467, 1996; Cao et al., J. Biol. Chem. 272, in press, 1997).
  • the inhibitory activity of Kl-5 on BSE cells was tested at low concentrations (0.2-10 nM) and (B) at high concentration (20 nM-320 nM).
  • C The half maximal inhibition of Kl-5 on BCE cells was observed at approximately 50 pM.
  • D The inhibitory effect is reversible. After removal of Kl-5 from the conditioned medium, endothelial cells are able to proliferate in fresh DMEM medium containing 1 ng/ml of bFGF.
  • Fig. 3 Morphology ofKl-5-treated endothelial cells.
  • BCE cells stopped proliferation (B-D) as compared to control cells (A).
  • Fig. 4 Synergistic suppression of endopthelial cell growth by angiostatin andK5.
  • Kl-4 and K5 were obtained as prote- olytic fragments. These two endothelial cell inhibitors were added either separately or together to bovine capillary endothelial (BCE) cells stimulated by lng/ml basic fibroblast growth factor (bFGF). At the concentration of 1 nM, angiostatin did not exhibit endothelial cell inhibition. Kringle 5 inhibited endothelial cell proliferation by approximately 50%. When angiosta- tin and K5 were added together to BCE cells, approximately 95% suppres- sion of cell growth was detected, indicating that both fragments synergisti- cally inhibit endothelial cell proliferation.
  • BCE bovine capillary endothelial
  • bFGF basic fibroblast growth factor
  • Fig. 5 Antiangiogenic effect of Kl-5 on the chick embryo chorioallantoic membrane (CAM).
  • Methylcellulose disk containing various doses of Kl-5 was implanted on CAMs of day 6-old-embryos as described (Cao et al., J. Exp. Med. 182, 2069-2077, 1995).
  • the number of CAMs with avascular zones over the total number of CAMs is indi- cated as percentages.
  • Phosphate-buffered saline was used as a negative control.
  • Fig. 6 Suppression of primary tumor growth by Kl-5.
  • mice Approximately, 1 x 10 6 murine T241 fibrosarcoma tumor cells were subcutaneously implanted into each of 6-week-old C57B16/J mouse. The mice were systemically treated with 100 ⁇ l PBS or 2.5 mg/kg/day Kl-5 in 100 ⁇ l PBS once daily.
  • A Kl- 5-treated mice and a control mouse were photographed at day 20 of treatment.
  • B Tumor volumes were measured with a digital calipper and calculated according to a standard formula with x with x length x 0.52. The data represent average mean values ( ⁇ SEM).
  • Fig. 7. Detection of microvessel density by immunohistochemical staining of tumor tissue sections with anti-vWF antibodies.
  • A A control tumor section treated with PBS.
  • B and (C) Kl-5-treated tumor sections.
  • D Quantification of mirovessels of tumor tissue sections per high field.
  • compositions and methods are provided that are effective for inhibiting endothelial cell proliferation, modulating angiogenesis, and inhibiting unwanted angiogenesis, especially an- giogenesis related to tumor growth.
  • the present invention includes a protein endothelial cell proliferation inhibitor characterized as an approximately 452 amino acid sequence derivable from human plasminogen as kringles 1- 5. The amino acid sequence of the inhibitor may vary slightly between species.
  • the present invention provides methods and compositions for treating diseases and processes mediated by undesired and uncontrolled epithelial cell proliferation, such as angiogenesis, by administering to a human or animal having undesired endothelial cell proliferation a composition comprising approximately kringle 1-5 of human plasminogen capable of inhibiting en- dothelial cell proliferation in in vitro assays.
  • the isolated protein is at least approximately 80% pure, more desirably at least approximately 90% pure and even more desirable at least approximately 90% pure.
  • the present invention is particularly useful for treating, or for repressing the growth of, tumors.
  • Administration of the inhibitor to a human or animal with prevascularized metastasized tumors helps prevent the growth or expansion of those tumors.
  • the present invention also encompasses DNA sequences encoding the endothelial cell proliferation inhibitor, expression vectors containing DNA sequences encoding the endothelial cell proliferation inhibitor, and cells containing one or more expression vectors containing DNA sequences encoding the inhibitor.
  • the present invention further encompasses gene therapy methods whereby DNA sequences encoding the endothelial cell proliferation inhibitor are in-duced into a patient to modify in vivo inhibitor levels.
  • the present invention also includes diagnostic methods and kits for detection and measurement of the endothelial cell proliferation inhibitor in biological fluids and tissues, and for localization of the inhibitor in tissues and cells.
  • the diagnostic method and kit can be in any configuration well known to those of ordinary skill in the art.
  • the present invention also includes antibodies specific for the endothelial cell proliferation inhibitor and portions thereof, and antibodies that inhibit the binding of antibodies specific for the endothelial cell proliferation inhibitor. These antibodies can be polyclonal antibodies or monoclonal antibodies.
  • the antibodies specific for the endothelial cell proliferation inhibitor can be used in diagnostic kits to detect the presence and quantity of the inhibitor which is diagnostic or prognostic for the occurrence or recurrence of cancer or other disease mediated by angiogenesis.
  • Antibodies specific for the endothelial cell proliferation inhibitor may also be administered to a human or animal to passively immunize said human or animal against the inhibitor, thereby reducing angiogenic inhibition.
  • the present invention also includes diagnostic methods and kits for detec- ting the presence and quantity of antibodies that bind the endothelial cell proliferation inhibitor in body fluids.
  • the diagnostic method and kit can be in any configuration well known to those of ordinary skill in the art.
  • the present invention also includes anti-inhibitor receptor-specific antibo- dies that bind to the inhibitor's receptor and transmit the appropriate signal to the cell and act as agonists or antagonists.
  • the present invention also includes inhibitor peptide fragments and analogs that can be labeled isotopically or with other molecules or proteins for use in the detection and visualization of the inhibitor binding sites with techniques, including, but not limited to, positron emission tomography, autora- diography, flow cytometry, radioreceptor binding assays, and immunohis- tochemistry.
  • inhibitor peptides and analogs also act as agonists and antagonists at the inhibitor receptor, thereby enhancing or blocking the biological activity of the endothelial cell proliferation inhibitor.
  • Such peptides are used in the isolation of the receptor molecules capable or specifically binding to the inhibitor.
  • the present invention also includes the endothelial cell proliferation inhibitor, inhibitor fragments, antisera specific for the inhibitor, and inhibitor receptor agonists and receptor antagonists linked to cytotoxic agents for therapeutic and research applications.
  • inhibitors, fragments thereof, antisera specific therefore, inhibitor receptor agonists and inhibitor receptor antagonists are combined with pharmaceutically acceptable excipients, and optionally sustained- release compounds or compositions, such as biodegradable polymers and matrices, to form therapeutic compositions.
  • the present invention includes molecular probes for the ribonucleic acid and deoxyribonucleic acid involved in transcription and translation of the endothelial cell proliferation inhibitor. These molecular probes are useful for detecting and measuring inhibitor biosynthesis in tissues and cells.
  • the inhibitor may be isolated from plasminogens, such as human plasminogen, or synthesized by chemical or biological methods (e.g. cell culture, recombinant gene expression, peptide synthesis and in vitro enzymatic catalysis of plasminogen or plasmin to yield active inhibitor).
  • Recombinant techniques include gene amplification from DNA sources using the polyme- rase chain reaction (PCR), and gene amplification from RNA sources using reverse transcriptase/PCR.
  • the present invention also encompasses a composition comprising a vector containing a DNA sequence encoding the endothelial cell proliferation inhibitor, wherein the vector is capable of expressing the inhibitor when present in a cell, a composition comprising a cell containing a vector, wherein the vector contains a DNA sequence encoding the inhibitor fragments or analogs thereof, and wherein the vector is capable of expressing the inhibitor when present in the cell, and a method comprising implanting into a human or non-human animal a cell containing a vector, wherein the vector contains a DNA sequence encoding the inhibitor, wherein the vector is capable of expressing the inhibitor when present in the cell.
  • the term "substantially similar” or “substantially homologous” when used in reference to the inhibitor amino acid and nucleic acid sequences means an amino acid sequence having endothelial cell proliferation inhibiting activity and and having a molecular weight of approximately 55kDa, which also has a high degree of sequence homology to the protein having the specific N-terminal amino acid sequence disclosed herein, or a nucleic acid sequence that codes for an endothelial cell proliferation inhibitor having a molecular weight of approximately 55kDa and a high degree of homology to the having the specific N-te ⁇ ninal amino acid sequence disclosed herein.
  • a high degree of homology means at least approximately 80% amino acid homology, desirably at least approximately 90% amino acid homology, and more desirably at least approximately 95% amino acid homology.
  • endothelial inhibiting activity means the capability of a molecule to inhibit angiogenesis in general and, for example, to inhibit the growth of bovine capillary endothelial cells in culture in the presence of fibroblast growth factor.
  • the present invention also includes the detection of the inhibitor in body fluids and tissues for the purpose of diagnosis or prognosis of diseases such as cancer.
  • the present invention also includes the detection of inhibitor binding sites and receptors in cells and tissues.
  • the present invention also includes methods of treating or preventing angiogenic diseases and processes including, but not limited to, arthritis and tumors by stimulating the pro- duction of the inhibitor, and/or by administering isolated inhibitor, or desirable purified inhibitor, or inhibitor agonists or antagonists, and/or inhibitor-specific antisera or antisera directed against inhibitor-specific antisera to a patient. Additional treatment methods include administration of the inhibitor, biologically active fragments thereof, inhibitor analogs, inhibitor- specific antisera, or inhibitor receptor agonists and antagonists linked to cytotoxic agents.
  • Passive antibody therapy using antibodies that specifically bind the inhibitor can be employed to modulate angiogenic-dependent processes such as re- production; development, and wound healing and tissue repair.
  • antisera directed to the Fab regions of inhibitor-specific antibodies can be administered to block the ability of endogenous inhibitor-specific antisera to bind inhibitor.
  • the present invention also encompasses gene therapy, whereby the gene encoding the inhibitor is regulated in a patient.
  • gene therapy encompasses incorporation of DNA sequences into somatic cells or germ line cells for use in either ex vivo or in vivo therapy. Gene therapy functions to replace genes, augment normal or abnormal gene function, and to combat infectious diseases and other pathologies.
  • Strategies for treating these medical problems with gene therapy include therapeutic strategies, such as identifying the defective gene and then adding a functional gene to either replace the function of the defective gene or to augment a slightly functional gene; or prophylactic strategies, such as adding a gene to the product protein that will treat the condition or that will make the tissue or organ more susceptible to a treatment regimen.
  • a nucleic acid sequence coding for the inhibitor may be placed in a patient and thus prevent occurrence of angi- ognesis; or a gene that makes tumor cells more susceptible to radiation could be inserted and then radiation of the tumor would cause increased killing of the tumor cells.
  • Non-viral vectors may be used which include liposomes coated with DNA.
  • liposome/DNA complexes may be directly injected intravenously into the patient. It is believed that the liposome/DNA complexes are concentrated in the liver where they deliver the DNA to macrophages and Kupfter cells. These cells are long lived and thus provide long term expression of the delivered DNA.
  • vectors or the "naked" DNA of the gene may be directly injected into the desired organ, tissue or tumor for targeted delivery of the therapeutic DNA.
  • Gene therapy methodologies can also be described by delivery site. Fundamental ways to deliver genes include ex vivo gene transfer, in vivo gene transfer and in vitro gene transfer.
  • ex vivo gene transfer cells are taken from the patient and grown in cell culture. The DNA is transfected into the cells, the transfected cells are expanded in number and then reimplanted in the patient.
  • in vitro gene transfer the transformed cells are cells growing in culture, such as tissue culture cells, and not particular cells from a particular patient. These "laboratory cells" are transfected, the transfected cells are selected and expanded for either implantation into a patient or for other uses.
  • In vivo gene transfer involves introducing the DNA into the cells of the patient when the cells are within the patient.
  • Methods include using a nonin- fectous virus to deliver the gene in the patient or injecting naked DNA into a site in the patient and the DNA is taken up by a percentage of cells in which the gene product protein is expressed.
  • the other methods described herein such as use of a "gene gun” may be used for in vitro insertion ot endothelial cell proliferation inhibitor DNA or inhibitor regulatory sequences.
  • Chemical methods of gene therapy may involve a lipid based compound, not necessarily a liposome, to ferry the DNA across the cell membrane.
  • Lipofectins or cytofectins make a complex that can cross the cell membrane and provi- de the DNA into the interior of the cell.
  • Another chemical method uses receptor-based endocytosis, which involves binding a specific ligand to a cell surface receptor and developing and transporting it across the cell membrane. The ligand binds to the DNA and the whole complex is transported into the cell. The ligand gene complex is injected into the blood stream and then target cells that have the receptor will specifically bind the ligand and transport the ligand-DNA complex into the cell.
  • viral vectors to insert genes into cells.
  • altered retrovirus vectors have been used in ex vivo met- hods to introduce genes into peripheral and tumor-infiltrating lymphocytes, hepatocytes, epidermal cells, myocytes, or other somatic cells. These altered cells are then introduced into the patient to provide the gene product from the inserted DNA.
  • Viral vectors have also been used to insert genes into cells using in vivo protocols.
  • tissue-specific expression of fo- reign genes cis-acting regulatory elements or promoters that are known to be tissue specific can be used. Alternatively, this can be achieved using in situ delivery of DNA or viral vectors to specific anatomical sites in vivo.
  • gene transfer to blood vessels in vivo was achieved by implanting in vitro transduced endothelial cells in chosen sites on arterial walls.
  • the virus infected surrounding cells which also expressed the gene product.
  • a viral vector can be delivered directly to the in vivo site, by a catheter for example, thus allowing only certain areas to be infected by the virus, and providing long-term, site specific gene expression.
  • retrovirus vectors has also been demonstrated in mammary tissue and hepatic tissue by injection of the altered virus into blood vessels leading to the organs.
  • Viral vectors that have been used for gene therapy protocols include but are not limited to, retroviruses, other RNA viruses such as polio virus or Sind- bis virus, adenovirus, adeno-associated virus, herpes viruses, SV 40, vacci- nia and other DNA viruses.
  • Replication-defective murine retroviral vectors are the most widely utilized gene transfer vectors.
  • Murine leukemia retroviruses are composed of a single strand RNA complexed with a nuclear core protein and polymerase (pol) enzymes, encased by a protein core (gag) and surrounded by a glycoprotein envelope (env) that determines host range.
  • retroviral vector systems exploit the fact that a minimal vector containing the 5' and 3' LTRs and the packaging signal are sufficient to allow vector packaging, infection, and integration into target cells providing that the viral structural proteins are supplied in trans in the packaging cell line. Fundamental advantages of retroviral vectors for gene transfer include efficient infection and gene expression in most cell types, precise single copy vector into target cell chromosomal DNA, and ease of manipulation of the retroviral genome.
  • the adenovirus is composed of linear double stranded DNA complexed with core proteins and surrounded with capsid proteins. Advances in molecular virology have led to the ability to exploit the biology of these organisms in order to create vectors capable of transducing novel genetic sequences into target cells in vivo.
  • Adenoviral-based vectors will express gene product peptides at high levels.
  • Adenoviral vectors have high efficiencies of infectivity, even with low titers of virus. Additionally, the virus is fully infective as a cell free virion so injection of producer cell lines are not necessary. Another potential advantage to adenoviral vectors is the ability to achieve long term expression of heterologous genes in vivo.
  • DNA delivery include fusogenic lipid vesicles such as liposomes or other vesicles for membrane fusion, lipid particles of DNA incorporating cationic lipid such as lipofectin, polylysine-mediated transfer of DNA, direct injection of DNA, such as microinjection of DNA into germ or somatic cells, pneumatically delivered DNA-coated particles, such as the gold particles used in a "gene gun", and inorganic chemical approaches such as calcium phosphate transfection.
  • Another method, ligand mediated gene therapy involves complexing the DNA with specific ligands to form ligand-DNA conjugates to direct the DNA to specific cells or tissue.
  • Non-integration of the transfected DNA would allow the transfection and expression of gene product proteins in te ⁇ ninally differentiated, non-proliferative tissues for a prolonged period of time without fear of mutational insertions, deletions, or alterations in the cellular or mi- tochondrial genome. Long-term, but not necessarily permanent transfer of therapeutic genes into specific cells may provide treatments for genetic di- seases or for prophylactic use.
  • the DNA could be reinjected periodically to maintain the gene product level without mutations occuring in the genomes of the recipient cells.
  • Non-integration of exogenous DNAs may allow for the presence of several different exogenous DNA constructs within one cell with all of the constructs expressing various gene products.
  • Particle-mediated gene transfer methods were first used in transforming plant tissue. With a particle bombardment device, or "gene gun", a motive force is generated to accelerate DNA-coated high density particles (such as gold or tungsten) to a high velocity that allows penetration of the target organs, tissues or cells.
  • Particle bom- bardment can be used in in vitro systems, or with ex vivo or in vivo techniques to introduce DNA into cells, tissues or organs.
  • Electroporation for gene transfer uses an electrical current to make cells or tissues susceptible to electroporation-mediated gene transfer. A brief electric impulse with a given field strength is used to increase the permeability of a membrane in such a way that DNA molecules can penetrate into the cells. This technique can be used in in vitro systems, or with ex vivo or in vivo techniques to introduce DNA into cells, tissues or organs.
  • Carrier mediated gene transfer in vivo can be used to rransfect foreign DNA into cells.
  • the carrier-DNA-complex can be conveniently introduced into body fluids or the bloodstream and then site specifically directed to the target organ or tissue in the body.
  • Both liposomes and polycations, such as polylysine, lipofectins or cytofectins can be used.
  • Liposomes can be developed which are cell specific or organ specific and thus the foreign DNA carried by the liposome will be taken up by target cells. Injection of immunoliposomes that are targeted to a specific receptor on certain cells can be used as a convenient method of inserting the DNA into the cells bearing the receptor.
  • Another carrier system that has been used is the asialoglycopor- tein/polylysine conjugate system for carrying DNA to hepatocytes for in vivo gene transfer.
  • the transfected DNA may also be complexed with other kinds of carriers so that the DNA is carried to the recipient cell and then resides in the cytoplasm or in the nu- cieoplasm.
  • DNA can be coupled to carrier nuclear proteins in specifically engineered vesicle complexes and carried directly into the nucleus.
  • Gene regulation of the inhibitor of the present invention may be accomplished by a(iministering compounds that bind to the gene for the inhibitor, or control regions associated with the gene, or its corresponding RNA transcript to modify the rate of transcription or translation.
  • cells transfected with a DNA sequence en- coding the inhibitor may be administered to a patient to provide an in vivo source of inhibitor.
  • cells may be transfected with a vector containing a nucleic acid seqence encoding the inhibitor.
  • vector means a carrier that can contain or associate with specific nucleic acid seqnences, which functions to transport the specific nuclic acid sequences into a cell.
  • vectors include plasmids and infective microorganisms such as viruses, or non-viral vectors such as ligand-DNA conjugates, liposomes, lipid- DNA complexes. It may be desirable that a recombinant DNA molecule comprising an endothelial cell proliferation inhibitor DNA sequence is ope- ratively linked to an expression control sequence to form an expression vector capable of expressing the inhibitor.
  • the transfected cells may be cells derived from the patient's normal tissue, the patient's diseased tissue, or may be non-patient cells.
  • tumor cells removed from a patient can be transfected with a vector capable of expressing the inhibitor protein of the present invention and re- introduced into the patient.
  • the transfected tumor cells produce levels of inhibitor in the patient that inhibit the growth of the tumor.
  • Patients may be human or non- human animals.
  • inhibitor DNA may be directly injected, without the aid of a carrier, into a patient.
  • inhibitor DNA may be injected into skin, muscle or blood.
  • Inhibitor expression may continue for a long-period of time or inhibitor DNA may be administered periodically to maintain a desired level of the inhibitor protein in the cell, the tissue or organ or biological fluid.
  • angiogenic peptides e.g. aFGF, bFGF, VEGF, IL-8, GM-CSF, etc.
  • angiogenic peptides e.g. aFGF, bFGF, VEGF, IL-8, GM-CSF, etc.
  • angiogenic peptides must be produced in an amount sufficient to overcome the action of endothelial cell inhibitor (inhibitors of angiogenesis) for a primary tumor to continue to expand its population. Once such a primary tumor is growing well, it continues to release endothelial cell inhibitors into the circulation.
  • these inhibitors act remotely at a distance from the primary tumor, target capillary endothelium of a ⁇ metastasis from an intravascular direction, and continue to circulate.
  • the capillary endothelium in its neighborhood could be inhibited by incoming inhibitor.
  • Production of the approximately endothelial cell proliferation inhibitor of the pre- sent invention in accomplished using similar techniques can be accomplished using recombinant DNA techniques including the steps of (1) identifying and purifying the inhibitor as described herein and exemplified by the Figures. (2) determining the N-terminal amino acid sequence of the purified inhibitor, (3 ) synthetically generating 5' and 3' DNA oligonucleotide primers for the inhibitor sequence, (4) amplify- ing the inhibitor gene sequence using polymerase, (5) inserting the amplfied sequence into an appropriate vector such as an expression vector, (6) inserting the gene containing vector into a microorganism or other expression system capable of expressing the inhibitor gene, and (7) isolating the recombinantly produced inhibitor.
  • Appropriate vectors include viral, bacterial and eukaryotic (such as yeast) ex- pression vectors.
  • viral, bacterial and eukaryotic (such as yeast) ex- pression vectors are more fully described in laboratory manuals such as "Molecular Cloning: A Laboratory Manual” Second Edition by Sambrook et al., Cold Spring Harbor Press, 1989, which is incorporated herein by reference. The contents of all references cited in this application are included herein by reference.
  • the amino acid sequence of the inhibitor can be determined, for example by automated peptide sequencing methods.
  • the DNA sequence can be determined using manual or automated sequencing methods well know in the art.
  • the nucleic acid sequence in turn provides information regarding the amino acid sequence.
  • peptide fragments can be synthesized by techniques well known in the art, as exemplified bv "Solid Phase Peptide Synthesis: A Practical Approach” E. Atherton and R.C. Sheppard. IRL Press, Oxford, England. Multiple fragments can be synthesized which are subsequently linked together to form larger fragments. These synthetic peptide fragments can also be made with amino acid substitutions at specific locations in order to test for agonistic and antagonistic activity in vitro and in vivo. Peptide fragments that possess high affinity binding to tissues can be used to isolate receptors the bind the inhibitor on affinity columns.
  • the inhibitor is effective in treating diseases or processes such as angiogenesis, that are mediated by, or involve, endothelial cell proliferation.
  • the present invention includes the method of treating an angiogenesis mediated disease with an effective amount of inhibitor, or a biologically active fragment thereof, or combinations of inhibitor fragments that collectively possess anti-angiogenic activity or inhibitor agonists and antagonists.
  • the angiogenesis mediated diseases include, but are not limited to, solid tumors; blood born tumors such as leukemias; tumor metastasis; benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; rheumatoid arthritis; psoriasis; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis; Osier- Webber Syndrome; myocardial angiogenesis; plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; and wound granulation.
  • solid tumors such as leukemias
  • tumor metastasis such as leukemias
  • benign tumors for example hemangiomas, acoustic
  • the inhibitor is useful in the treatment of diseases of excessive or abnormal stimulation of endothelial cells. These diseases include, but are not limited to, intestinal adhesions, atherosclerosis, scleroderma, and hypertrophic scars, i.e., keloids.
  • the inhibitor can be used as a birth control agent by preventing vascularization required for embryo implantation.
  • the inhibitor is useful in the treatment of diseases that have angiogenesis as a pathologic consequenee such as cat scratch disease (Rochele minalia quintosa) and ulcers (Helicobacter pylori).
  • the synthetic peptide fragments of the inhibitor have a variety of uses.
  • the peptide that binds to receptor capable of binding the inhibitor with high specificity and avidity is radiolabeled and employed for visualization and quantitation of binding sites using autoradiographic and membrane binding techniques.
  • labeling inhibitor or peptide fragments thereof with short lived isotopes enables visualization of receptor binding sites in vivo using positron emission tomography or other modern radiographic techniques in order to locate tumors with inhibitor binding sites.
  • Cytotoxic agents such as ricin are linked to the inhibitor, and high affinity peptide fragments thereof, thereby providing a tool for destruction of cells that bind the inhibitor. These cells may be found in many locations, including but not limited to, micrometastases and primary tumors. Peptides linked to cytotoxic agents are infused in a manner designed to maximize delivery to the desired location. For example, delivery may be accomplished through a cannula into vessels supplying the target site or directly into the target. Such agents are also delivered in a controlled manner through osmotic pumps coupled to infusion cannulae. A combination of inhibitor antagonists may be co-applied with stimulators of angiogenesis to increase vascularization of tissue. This therapeutic regimen provides an effective means of destroy- ing metastatic cancer.
  • the inhibitor may be used in combination with other compositions and procedures for the treatment of diseases.
  • a tumor may be treated conventionally with surgery, radiation or chemotherapy combined with the inhibitor and then the inhibitor may be subsequently administered to the patient to extend the dormancy of micrometastases and to stabilize and inhibit the growth of any residual primary tu- mor.
  • the inhibitor, fragments thereof, inhibitor-specific antisera, inhibitor receptor agonists and antagonists, or combinations thereof are combined with pharmaceutically acceptable excipients, and optionally sustained-release matrix, such as biodegradable polymers, to form therapeutic compositions.
  • a sustained-release matrix is a matrix made of materials, usually polymers, which are degradable by enzymatic or acid/base hydrolysis or by dissolution. Once inserted into the body, the matrix is acted upon by enzymes and body fluids.
  • the sustained-release matrix desirably is chosen from biocompatible materi- als, such as liposomes, polylactides (polylactic acid), polyglycolide (polymer of glycolic acid), polylactide co-glycolide (co-polymers of lactic acid and glycolic acid), polyanhydrides, poly(ortho)esters, polypeptides, hyaluronic acid, collagen, chondroitin sulfate, carboxylic acids, fatty acids, phospholipids, polysaccharides, nucleic acids, polyamino acids, amino acids such as phenylalanine, tyrosine, isoleu- cine, polynucleotides, polyvinyl propylene, polyvinylpyrrolidone and silicone.
  • a preferred biodegradable matrix is a matrix of one of either polylactide, polyglycolide, or polylactide co-glycolide (co-polymers of lactic acid and glycolic acid).
  • the angiogenesis-modulatmg therapeutic composition of the present invention may be a solid, liquid or aerosol and may be administered by any known route of administration.
  • solid therapeutic compositions include pills, creams, and implantable dosage units.
  • the pills may be administered orally, the therapeutic creams may be administered topically.
  • the implantable dosage units may be administered locally, for example at a tumor site, or which may be implanted for syste- mic release of the therapeutic angiogenesis modulating composition, for example subcutaneously.
  • liquid composition include formulations adapted for injection subcutaneously, intravenously, intraarterially and formulations for topical and intraocular_acln ⁇ inistration.
  • aerosol formulations include inhaler formulation for administration to the lungs.
  • the inhibitor protein of the present invention also can be used to generate antibodies that are specific for the inhibitor and its receptor.
  • the antibodies can be either polyclonal antibodies or monoclonal antibodies. These antibodies that specifically bind to the inhibitor or inhibitor receptors can be used in diagnostic methods and kits that are well known to those of ordinary skill in the art to detect or quantify the inhibitor levels or inhibitor receptors levels in a body fluid or tissue. Results from these tests can be used to diagnose or predict the occurrence or recurrence of a cancer and other angiogenic mediated diseases.
  • the inhibitor also can be used to develop a diagnostic method and kit to detect and quantify antibodies capable of binding the inhibitor. These kits would permit detection of circulating inhibitor-specific antibodies. Patients that have such circulating anti-inhibitor antibodies may be more likely to develop multiple tumors and cancers, and may be more likely to have recurrences of cancer after treatments or periods of remission.
  • the Fab fragments of these antibodies may be used as antigens to generate anti-inhibitor-specific Fab-fragment antisera which can be used to neutralize anti-inhibitor antibodies. Such a method would reduce the removal of circulating inhibitor by anti-inhibitor antibodies, thereby effectively elevating circulating inhibitor levels.
  • Another aspect of the present invention is a method of blocking the action of excess endogenous inhibitor. This can be done by passively immunizing a human or animal with antibodies specific for the undesired inhibitor in the system. This treatment can be important in treating abnormal ovulation, menstruation and placentation, and vasculogenesis. This provides a useful tool to examine the effects of inhibitor removal on metastatic processes.
  • the Fab fragment of inhibitor-specific antibodies contains the binding site for inhibitor. This fragment is isolated from inhibitor-specific antibodies usig_techniques known to those skilled in the art.
  • the Fab fragment of inhibitor-specific antisera are used as antigens to generate production of anti-Fab fragment serum. Infusion of this antiserum against the Fab fragments specific for the inhibitor prevents the inhibitor from binding to inhibitor antibodies.
  • Therapeutic be- nefit is obtained by neutralizing endogenous anti-inhibitor antibodies by blocking the binding of inhibitor to the Fab fragments or anti-inhibitor.
  • the net effect of this treatment is to facilitate the ability of endogenous circulating inhibitor to reach target cells, thereby decreasing the spread of metastases.
  • the present invention is contemplated to include any derivatives of the inhibitor that have endothelial cell proliferation inhibitor activity.
  • the present invention includes the entire inhibitor protein, derivatives of the inhibitor protein and biologically-active fragments of the inhibitor protein. These include proteins with inhibitor activity that have amino acid substitutions or have sugars or other molecules attached to amino acid functional groups.
  • the present invention also includes genes that code for the inhibitor and the inhibitor receptor, and to proteins that are expressed by those genes.
  • the proteins and protein fragments with the inhibitor activity described above can be provided as isolated and substantially purified proteins and protein fragments in pharmaceutically acceptable formulations using formulation methods known to those of oridinary skill in the art. These formulations can be administered by standard routes. In general, the combinations may be administered by the topical, trans- dermal, intraperitoneal, intracranial, intracerebroventricular, intracerebral, intra- vaginal, inrrauterine, oral, rectal or parenteral (e.g., intravenous, intraspinal. subcutaneous or intramuscular) route.
  • the inhibitor may be incorporated into biodegradable polymers allowing for sustained release of the compound, the polymers being implanted in the vicinity of where drug delivery is desired, for example, at the site of a tumor or implanted so that the inhibitor is slowly released systemi- cally.
  • Osmotic minipumps may also be used to provide controlled delivery of high concentrations of the inhibitor through cannulae to the site of interest, such as directly into a metastatic growth or into the vascular supply to that tumor.
  • the biodegradable polymers and their use are described, for example, in detail in Brem et al., J. Neurosurg. 74:441-446 (1991), which is hereby incorporated by reference in its entirety.
  • the dosage of the inhibitor of the present invention will depend on the disease state or condition being treated and other clinical factors such as weight and condition of the human or animal and the route of administration of the compound. For treating humans or animals, approximately 5 mg/kg/day, administered once a day, sppresses tumor growth to >50%. In the same dosages, angiostatin does not have any effect. Depending upon the half-life of the inhibitor in the particular animal or human, the inhibitor can be adn imstered between several times per day to once a week. It is to be understood that the present invention has application for both human and veteri- nary use. The methods of the present invention contemplate single as well as multiple administrations, given either simultaneously or over an extended period of time.
  • the inhibitor formulations include those suitable for oral, rectal, ophthalmic (including intravitreal or intracameral, nasal, topical (including buccal and sublin- gual), intrauterine, vaginal or parenteral (including subcutaneous, intraperitoneal, intramuscular, intravenous, intradermal, intracranial, intratracheal, and epidural) administration.
  • the inhibitor formulations may conveniently be presented in unit dosage form and may be prepared by conventional pharmaceutical techniques. Such techniques include the step of bringing into association the active ingredient and the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
  • Formulations suitable for parenteral administration include aqueous and non- aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacte- riostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the formulations may be presen- ted in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water for injections, immediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
  • Preferred unit dosage formulations are those containing a daily dose or unit, daily sub-dose, or an appropriate fraction thereof, of the administered ingredient.
  • the formulations of the present invention may include other agents conventional in the art having regard to the type of formulation in question.
  • cytotoxic agents may be incorporated or otherwise combined with inhibitor proteins, or biologically functional peptide fragments thereof, to provide dual therapy to the patient.
  • Angiogenesis inhibiting peptides of the present invention can be synthesized in a standard microchemical facility and purity checked with HPLC and masspectrop- hotometry. Methods of peptide synthesis, HPLC purification and mass spectropho- tometry are commonly known to those skilled in these art. Inhibitor peptides and inhibitor receptors peptides are also produced in recombinant E. coli or yeast expression systems, and purified with column chromatography.
  • Different peptide fragments of the intact inhibitor molecule can be synthesized for use in several applications including, but not limited to the following; as antigens for the development of specific antisera, as agonists and antagonists active at inhibitor binding sites, as peptides to be linked to, or used in combination with, cyto- toxic agents for targeted killing of cells that bind the inhibitor.
  • the amino acid sequences that comprise these peptides are selected on the basis of their position on the exterior regions of the molecule and are accessible for binding to antisera.
  • the amino and carboxyl termini of the inhibitor, as well as the mid-region of the molecule are represented separately among the fragments to be synthesized.
  • peptide sequences are compared to known sequences using protein sequence databases such as GenBank, Brookhaven Protein, SWISS-PROT, and PIR to determine potential sequence homologies. This information facilitates elimination of sequences that exhibit a high degree of sequence homology to other molecules, the- reby enhancing the potential for high specificity in the development of antisera, agonists and antagonists to the inhibitor.
  • Inhibitor and inhibitor derived peptides can be coupled to other molecules using standard methods.
  • the amino and carboxyl termini of the inhibitor both contain ty- rosine and lysine residues and are isotopically and nonisotopically labeled with many techniques, for example radiolabeling using conventional techniques (tyrosine residues- chloramine T, iodogen, lactoperoxidase; lysine residues- Bolton-Hunter reagent). These coupling techniques are well known to those skilled in the art.
  • tyrosine or lysine is added to fragments that do not have these residues to facilitate labeling of reactive amino and hydroxyl groups on the peptide.
  • the coupling technique is chosen on the basis of the functional groups available on the amino acids including, but not limited to amino, sulfhydral, carboxyl, amide, phenol and imidazole.
  • Various reagents used to effect these couplings include among others, glutaraladehyde, diazotized benzidine, carbodiimide, and p-benzoquinone.
  • In- hibitor peptides are chemically coupled to isotopes, enzymes, carrier proteins, cytotoxic agents, fluorescent molecules, chemiluminescent, bioluminescent and other compounds for a variety of applications. The efficiency of the coupling reaction is determined using different techniques appropriate for the specific reaction.
  • radiolabeling of an inhibitor peptide with I is accomplished using chlo- ramine T and Na 125 I of high specific activity.
  • the reaction is terminated with sodium metabisulfite and the mixture is desalted on disposable columns.
  • the labeled peptide is eluted from the column and fractions are collected. Aliquots are removed from each fraction and radioactivity measured in a gamma counter. In this manner, the unreacted Na I is separated from the labeled inhibitor peptide.
  • the peptide fractions with the highest specific radioactivity are stored for subsequent use such as analysis of the ability to bind to inhibitor antisera.
  • Another application of peptide conjugation is for production of polyclonal antisera.
  • inhibitor peptides containing lysine residues are linked to purified bovine serum albumin using glutaraldehyde.
  • the efficiency of the reaction is determi- ned by measuring the incorporation of radiolabeled peptide. Unreacted glutaraldehyde and peptide are separated by dialysis. The conjugate is stored for subsequent use.
  • Antiserum specific for the inhibitor, inhibitor analogs, peptide fragments of the in- hibitor and the inhibitor receptor can be generated. After peptide synthesis and purification, both monoclonal and polyclonal antisera are raised using established techniques known to those skilled in the art. For example, polyclonal antisera may be raised in rabbits, sheep, goats or other animals. Inhibitor peptides conjugated to a carrier molecule such as bovine serum albumin, or inhibitor itself, is combined with an adjuvant mixture, emulsified and injected subcutaneously at multiple sites on the back, neck, flanks, and sometimes in the rootpads. Booster injections are made at regular intervals, such as every 2 to 4 weeks.
  • Blood samples are obtained by veni- puncture, for example using the marginal ear veins after dilation, approximately 7 to 10 days after each injection.
  • the blood samples are allowed to clot overnight at 4°C and are centrifuged at approximately 2400 X g at 4°C for about 30 minutes.
  • the serum is removed, aliquoted, and stored at 4 C for immediate use for subsequent analysis.
  • All serum samples from generation of polyclonal antisera or media samples from production of monoclonal antisera are analyzed for determination of antibody titer. Titer is established through several means, for example, using dot blots and density analysis, and also with precipitation of radiolabeled peptide-antibody complexes using protein A, secondary antisera, cold ethanol or charcoal-dextran followed by activity measurement with a gamma counter.
  • the highest titer antisera are also puri- fied on affinity columns which are commercially available.
  • Inhibitor peptides are coupled to the gel in the affinity column. Antiserum samples are passed through the column and anti-inhibitor antibodies remain bound to the column. These antibodies are subsequently eluted, collected and evaluated for determination of titer and specificity.
  • the highest titer inhibitor-specific antisera is tested to establish the following; a) optimal antiserum dilution for highest specific binding of the antigen and lowest non-specific binding, b) the ability to bind increasing amounts of inhibitor peptide in a standard displacement curve, c) potential cross-reactivity with related peptides and proteins of related species, d) ability to detect inhibitor peptides in extracts of plasma, urine, tissues and in cell culture media.
  • Kits for measurement of inhibitor, and the inhibitor receptor are also contemplated as part of the present invention.
  • Antisera that possess the highest titer and specificity and can detect inhibitor peptides in extracts of plasma, urine, tissues, and in cell culture media are further examined to establish easy to use kits for rapid, reliable, sensitive, and specific measurement and localization of inhibitor.
  • assay kits include but are not limited to the following techniques; competitive and non- competitive assays, radioimmunoassay, bioluminescence and hemiluminescence assay, fluorometric assays, sandwich assays, immunoradiometric assays, dot blots, en- zyme linked assays including ELISA, microtiter plates, antibody coated strips or dipsticks for rapid monitoring of urine or blood, and immunocytochemistry.
  • competitive and non- competitive assays radioimmunoassay, bioluminescence and hemiluminescence assay, fluorometric assays, sandwich assays, immunoradiometric assays, dot blots, en- zyme linked assays including ELISA, microtiter plates, antibody coated strips or dipsticks for rapid monitoring of urine or blood, and immunocytochemistry.
  • competitive and non- competitive assays radioimmunoassay, bioluminescence and hemiluminescence assay, fluorometric as
  • a radioimmunoassay (RIA) kit One example of an assay kit commonly used in research and in the clinic is a radioimmunoassay (RIA) kit.
  • RIA radioimmunoassay
  • An inhibitor RJA is illustrated below. After successful radioiodination and purification of inhibitor or an inhibitor peptide, the antiserum possessing the highest titer is added at several dilutions to tubes containing a relati- vely constant amount of radioactivity, such as 10,000 cpm, in a suitable buffer system. Other tubes contain buffer or preimmune serum to determine the non-specific binding.
  • a dilution range (approximately 0, 1 pg to 10 ng) of the inhibitor peptide used for development or the antiserum is evaluated by adding known amounts of the peptide to tubes containing radiolabeled peptide and antiserum. After an additional incubation period, for example, 24 to 48 hours, protein A is added and the tubes centrifuged, supernatant removed and the radioactivity in the pellet counted. The displacement of the binding of radiolabeled inhibitor peptide by the unlabeled inhi- bitor peptide (standard) provides a standard curve. Several concentrations of other inhibitor peptide fragments, inhibitor from different species, and homologous peptides are added to the assay tubes to characterize the specificity of the inhibitor antiserum.
  • Extracts of various tissues including but not limited to primary and secondary tumors, Lewis lung carcinoma, cultures of inhibitor producing cells, placenta, uterus, and other tissues such as brain, liver, and intestine, are prepared. After lyophiliza- tion or Speed Vac of the tissue extracts, assay buffer is added and different aliquots are placed into the RIA tubes. Extracts of inhibitor producing cells produce displa- cement curves that are parallel to the standard curve, whereas extracts of tissues that do not produce inhibitor do not displace radiolabeled inhibitor from the inhibitor. In addition, extracts of urine, plasma, and cerebrospinal fluid from animals with Lewis lung carcinoma are added to the assay tubes in increasing amounts. Parallel displacement curves indicate the utility of the inhibitor assay to measure inhibitor in tissues and body fluids.
  • Tissue extracts that contain inhibitor are additionally characterized by subjecting aliquots to reverse phase HPLC. Eluate fractions are collected, dried in Speed Vac, reconstituted in RIA buffer and analyzed in the inhibitor RIA. The maximal amount of inhibitor immunoreactivity is located in the fractions corresponding to the elution position of inhibitor.
  • the assay kit provides instructions, antiserum, inhibitor or inhibitor peptide and possible radiolabeled inhibitor and/or reagents for precipitation of bound inhibitor- inhibitor antibody complexes.
  • the kit is useful for the measurement of inhibitor in biological fluids and tissue extracts of animals and humans with and without tumors.
  • This inhibitor immunohistochemistry kit provides instructions, inhibitor antiserum, and possibly blocking serum and secondary antiserum linked to a fluorescent molecule such as fluorescein isothiocyanate, or to some other reagent used to visualize the primary antiserum. Immunohistochemistry techniques are well known to those skilled in the art. This inhibitor immunohistochemistry kit permits localization of inhibitor in tissue sections and cultured cells using both light and electron microscopy. It is used for both research and clinical purposes. For example, tumors are biopsied or collected and tissue sections cut with a microtome to examine sites of inhibitor production. Such information is useful for diagnostic and possibly therapeutic purposes in the detection and treatment of cancer. Another method to visualize sites of inhi- bitor biosynthesis involves radiolabeling nucleic acids for use in in situ hybridization to probe for inhibitor messenger R A. Similarly, the inhibitor receptor can be localized, visualized and quantitated with immunohistochemistry techniques.
  • Human plasminogen was prepared from pooled human plasma by lysine- Sepharose chromatography as previously described (Cao et al., 1996, JBC, 271, 29461-29467). Purified human plasminogen was incubated in an alkaline solution. The digested mixture was loaded in a lysine-Sepharose co- lumn and Kl-5 was eluted with a 0-25 ⁇ -aminocaproic acid gradient. The
  • Kl-5 fraction was further purified on a Sephacryl-S200 column (2,5 x 70 to remove trace amounts of plasminogen contamination. The molecular weight was 55, 000 Dalton verified on SDS gel electrophoresis. Microsequencing analysis revealed that Kl-5 consists of a fragment corresponding to plasmi- nogen Lys 77-Arg 529.
  • Bovine capillary endothelial cells were maintained in DMEM with 10% heat-inactivated BCS, antibiotics and 3 ng/ml recombinant human bFGF. Cells were washed with PBS and dispersed in a 0,05% solution of trypsin. A cell suspension was made with DMEM, 10% BCS, 1% antibiotics and the concentration was adjusted to 25,000 cells/ml after hemocytometer count. Cells were plated onto gelatinized 24-well culture plates (0,5 ml/well) and were incubated (37°C in 10% C0 2 ) for 14h. The medium was replaced with 0,25 ml DMEM, 5% BCS and the test samples at different concentrations were applied.
  • Kl-5 from human plasminogen Human plasminogen was prepared from pooled human plasma by lysine- Sepharose chromatography as previously described (Cao et al., 1996, JBC, 271, 29461, 29467). approximately 40 mg of plasminogen in 4 ml of glyci- ne buffer (pH 10.5) was incubated with immobilized urokinase-activated plasmin (10 Mol of plasminogen / 1 Mol plasmin) for 24 h at 25°C.
  • the di- gested mixture was loaded in a lysine-Sepharose column (1.0 x 30 cm), and Kl-5 was eluted with a 0-25 ⁇ -aminocaproic acid gradient.
  • the Kl-5 fraction was further purified on a Sephadex G-75 column (2.6 x 90).
  • the molecular weight was 55,000 verified on SDS gel electrophoresis.
  • Micro- sequencing analysis revealed that Kl-5 consists of a fragment correspon- ding to plasminogen Lys 77 (78) - Arg 529 (530).
  • Bovine capillary endothelial cells were maintained in DMEM with 10% heat-inactivated BCS, antibiotics and 3 ng/ml recombinant human bFGF. Cells were washed with PBS and were dispersed in a 0.05% solution of trypsin. A cell suspension was made with DMEM, 10% BCS, 1% antibiotics and the concentration was adjusted to 25,000 cells/ml after hemocyto- meter count. Cells were plated onto gelatinized 24-well culture plates (0.5 ml/well) and were incubated (370C in 10% C02) for 14 h. The medium was replaced with 0.25 ml DMEM, 5% BCS and the test samples at different concentrations were applied.
  • mice Male 6-week-old C57B16/J mice were used for tumor studies.
  • Murine T241 fibrosarcoma cells (1 x 10 ⁇ ) growing in a log phase were harvested, resuspended in PBS, and implanted subcutaneously in the midline dorsum of each animal in a volume of 100 ⁇ l. Three mice were used in each treatment and control group.
  • Subcutaneous injections with either 100 ⁇ l of PBS or 100 ⁇ l of Kl-5 were begun shortly after injection of tumor cells and continued once a day, for a total of 20 days. Visible tumors were present after 24 h. Primary tumors were present after 24 h. Primary tumors were measured blindly using digital calipers on the days indicated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cette invention concerne une protéine capable de réguler la prolifération des cellules endothéliales, ainsi que diverses utilisations de cette protéine. Cette protéine possède un poids moléculaire d'environ 50 à 60 kDa et, de préférence, d'environ 55 kDa. Cette protéine comprend une séquence d'acide aminé qui est globalement similaire à celle du fragment de plasminogène Lys 78-Arg 530 d'une molécule de plasminogène.
EP98930036A 1997-06-26 1998-06-26 Domaines kringle 1-5 de plasminogene permettant de moduler l'angiogenese in vivo Withdrawn EP1001985A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US5082297P 1997-06-26 1997-06-26
US50822P 1997-06-26
US5597197P 1997-08-18 1997-08-18
US55971P 1997-08-18
SE9703057 1997-08-25
SE9703057A SE9703057D0 (sv) 1997-08-25 1997-08-25 Endothelial cell and angiogenesis inhibitor and methods of use
PCT/SE1998/001262 WO1999000420A1 (fr) 1997-06-26 1998-06-26 Domaines kringle 1-5 de plasminogene permettant de moduler l'angiogenese in vivo

Publications (1)

Publication Number Publication Date
EP1001985A1 true EP1001985A1 (fr) 2000-05-24

Family

ID=27355888

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98930036A Withdrawn EP1001985A1 (fr) 1997-06-26 1998-06-26 Domaines kringle 1-5 de plasminogene permettant de moduler l'angiogenese in vivo

Country Status (5)

Country Link
EP (1) EP1001985A1 (fr)
JP (1) JP2002510209A (fr)
AU (1) AU7951798A (fr)
CA (1) CA2295925A1 (fr)
WO (1) WO1999000420A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5801012A (en) 1996-09-17 1998-09-01 Northwestern University Methods and compositions for generating angiostatin
US7157556B1 (en) 1999-02-10 2007-01-02 The Children's Medical Center Corporation Deglycosylated kringle 1-3 region fragments of plasminogen and methods of use
WO2000047729A1 (fr) * 1999-02-10 2000-08-17 Entremed, Inc. Fragments dyglycosyles de region 1-5 kringle du plasminogene et ses methodes d'utilisation
AU4445100A (en) * 1999-04-14 2000-11-14 Karolinska Innovations Ab Kringle domains of plasminogen, capable of modulating angiogenesis in vivo
US7144854B1 (en) 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
DE60006100T2 (de) 1999-05-17 2004-07-01 Conjuchem, Inc., Montreal Lang wirkende insulinotrope peptide
AU8591901A (en) 2000-09-05 2002-03-22 Karolinska Innovations Ab Materials and methods relating to endothelial cell growth inhibitors
WO2002044328A2 (fr) * 2000-11-28 2002-06-06 Waisman David M Polypeptides anti-angiogeniques
EP1581164A4 (fr) 2002-12-13 2008-03-12 Mediomics Llc Compositions et methodes d'inhibition de la croissance des tumeurs et des metastases
EP3391902B1 (fr) 2015-12-18 2023-10-18 Talengen International Limited Plasminogène pour le traitement de l'angiocardiopathie diabétique
WO2017101868A1 (fr) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 Procédé pour empêcher et traiter une néphropathie diabétique
US10709771B2 (en) 2015-12-18 2020-07-14 Talengen International Limited Method for preventing or treating diabetic retinopathy
TWI653981B (zh) 2015-12-18 2019-03-21 深圳瑞健生命科學硏究院有限公司 Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury
CN110121357A (zh) * 2016-12-15 2019-08-13 泰伦基国际有限公司 一种治疗糖尿病的新方法
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
TW201822809A (zh) 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療高脂血症的方法
US11219669B2 (en) 2016-12-15 2022-01-11 Talengen International Limited Method for preventing and treating liver fibrosis
EP3556385A4 (fr) 2016-12-15 2020-12-30 Talengen International Limited Procédé pour atténuer une maladie cardiaque
US11938172B2 (en) 2017-06-19 2024-03-26 Talengen International Limited Method for regulating and controlling GLP-1/GLP-1R and drug

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997023500A1 (fr) * 1995-12-13 1997-07-03 The Children's Medical Center Corporation Inhibiteur de la proliferation des cellules endotheliales, et procede d'utilisation de celui-ci
ATE299888T1 (de) * 1996-05-03 2005-08-15 Abbott Lab Antiangiogenische peptiden, dafür kodierende polynukleotide und verfahren zur hemmung der angiogenesis
US5801012A (en) * 1996-09-17 1998-09-01 Northwestern University Methods and compositions for generating angiostatin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9900420A1 *

Also Published As

Publication number Publication date
AU7951798A (en) 1999-01-19
CA2295925A1 (fr) 1999-01-07
JP2002510209A (ja) 2002-04-02
WO1999000420A1 (fr) 1999-01-07

Similar Documents

Publication Publication Date Title
US5854221A (en) Endothelial cell proliferation inhibitor and method of use
US5885795A (en) Methods of expressing angiostatic protein
US5837682A (en) Angiostatin fragments and method of use
US7365159B2 (en) Angiostatin protein
EP0824546B1 (fr) Fragments d'angiostatine et procedes d'utilisation
EP1783215A1 (fr) angiostatine et procede d'utilisation de ladite substance pour inhiber l'angiogenese
WO1999000420A1 (fr) Domaines kringle 1-5 de plasminogene permettant de moduler l'angiogenese in vivo
EP0869970B1 (fr) Inhibiteur de la proliferation des cellules endotheliales et utilisation de celui-ci
WO2000061179A1 (fr) Domaines kringle du plasminogene capables de moduler l'angiogenese in vivo
CA2421251A1 (fr) Materiaux et procedes concernant des inhibiteurs de croissance cellulaire endotheliale
US6949511B1 (en) Methods of inhibiting angiogenesis via increasing in vivo concentrations of kringle region fragments of plasminogen
EP1867721A1 (fr) Fragments d'angiostatine et angiostatine d'agrégat et procédés d'utilisation
MXPA99011041A (en) Angiostatin fragments and method of use
AU7704998A (en) Angiostatin fragments and method of use
AU4440402A (en) Angiostatin fragments and method of use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991228

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20031208

17Q First examination report despatched

Effective date: 20031208

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070129